Drugs - MedicineNews.net - Medical Updates

Search results for "Xarelto"

Apixaban associated with lower risk of stroke and lower rates of major bleeding compared to Warfarin

The findings from a real-world data analysis of the U.S. Humana database, in which treatment with Apixaban ( Eliquis ) was associated with a significantly lower risk of stroke / systemic embolism and ... read article

Xarelto approved in the EU for secondary prevention after an acute coronary syndrome

The oral anticoagulant Xarelto ( Rivaroxaban ) has been approved by the European Commission for the prevention of atherothrombotic events ( cardiovascular death, myocardial infarction or stroke ) afte ... read article

Xarelto recommended for approval in the EU for the prevention of atherothrombotic events after an acute coronary syndrome

The European Committee for Medicinal Products for Human Use ( CHMP ) has recommended approval of oral anticoagulant Xarelto ( Rivaroxaban ) 2.5 mg twice-daily in combination with standard antiplatelet ... read article

Xarelto approved for treatment of pulmonary embolism and prevention of recurrent deep vein thrombosis and pulmonary embolism in the European Union

European Commission ( EC ) has approved oral anticoagulant Xarelto ( Rivaroxaban ) for the treatment of pulmonary embolism ( PE ) and the prevention of recurrent deep vein thrombosis ( DVT ) and pulmo ... read article

Anticlotting drugs: Xarelto approved by FDA to treat, reduce recurrence of blood clots

The FDA ( Food and Drug Administration ) has expanded the approved use of Xarelto ( Rivaroxaban ) to include treating deep vein thrombosis ( DVT ) or pulmonary embolism ( PE ), and to reduce the risk ... read article

Rivaroxaban, a new treatment for blood clots approved by NICE

Patients with blood clots can be now be offered Rivaroxaban ( Xarelto ) as an alternative to Warfarin ( Coumadin ) for the treatment of blood clots following latest guidance from NICE ( National Insti ... read article

Xarelto approved in the European Union for the prevention of stroke in patients with atrial fibrillation and in the treatment of deep vein thrombosis

Oral anticoagulant Xarelto ( Rivaroxaban ) has been approved by the European Commission ( EU ) for use in two new indications, making it the only new oral anticoagulant approved in three indications a ... read article

Atrial fibrillation: Rivaroxaban comparable to Warfarin in preventing stroke and other complications

A new anti-clotting drug, Rivaroxaban ( Xarelto ) is as effective as the standard medication in preventing stroke and blood clots, and does not increase bleeding risk among patients with the most comm ... read article

Xarelto is an effective and safe treatment for acute symptomatic deep vein thrombosis

Results of the Phase III EINSTEIN-DVT study have shown that the oral anticoagulant Rivaroxaban ( Xarelto ) achieved the primary efficacy and safety outcomes in the treatment of patients with acute, sy ... read article

New approach prevents thrombosis without increasing the risk of bleeding; an antibody, 3F7, blocks Factor XII

Researchers at Karolinska Institutet in Sweden, in collaboration with an international team, have developed an antibody, 3F7, which blocks a protein that is active in the coagulation system factor XII ... read article

Focus

Multiple sclerosis: FDA has approved Tecfidera

The FDA ( Food and Drug Administration ) has approved Tecfidera ( Dimethyl fumarate ) capsules to treat adults with relapsing forms of multiple sclerosis.Multiple sclerosis is a chronic, inflammatory, ... read article

Apremilast linked to significant and clinically meaningful improvements for the primary and major secondary endpoint in plaque psoriasis

Celgene has announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving Apremilast 30 mg BID monotherapy in both the ESTEEM 1 and 2 phase ... read article

Kadcyla, a new treatment for late-stage breast cancer, approved by Food and Drug Administration

The U.S. Food and Drug Administration ) has approved Kadcyla ( Ado-Trastuzumab Emtansine ), a new therapy for patients with HER2-positive, late-stage ( metastatic ) breast cancer.HER2 is a protein inv ... read article

FISSION and NEUTRINO trial: Sofosbuvir has met primary endpoints for hepatitis C

Results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide Sofosbuvir in combination with Ribavirin ( FISSION ) and in combination with Ribavirin ... read article

FDA has approved Eliquis to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation

The FDA ( Food and Drug Administration ) has approved the anti-clotting drug Eliquis ( Apixaban ), an oral tablet used to reduce the risk of stroke and dangerous blood clots ( systemic embolism ) in p ... read article

Chronic hepatitis C: Promacta for patients with thrombocytopenia to allow the initiation and maintenance of Interferon-based therapy

GlaxoSmithKline ( GSK ) has announced that the FDA ( Food and Drug Administration ) has approved Promacta ( Eltrombopag; in Europe: Revolade ) for the treatment of thrombocytopenia in patients with ch ... read article

Bosulif for chronic myelogenous leukemia, approved by Food and Drug Administration

The FDA ( Food and Drug Administration ) has approved Bosulif ( Bosutinib ) to treat chronic myelogenous leukemia ( CML ), a blood and bone marrow disease that usually affects older adults.An estimate ... read article

Increased risk of high-grade prostate cancer with 5-alpha reductase inhibitors

Men aged 55 and over with a normal digital rectal examination and PSA less than or equal to 3.0 ng/mL at baseline taking Finasteride 5 mg/day ( 5 times the dose of Propecia ) in the 7-year Prostate Ca ... read article